MedTrace Logo

2NN & CHARM Long-Term Follow-up Study

NCT00127972 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 763

Last updated 2007-04-30

No results posted yet for this study

Summary

It is desirable to obtain extended follow up data on subjects who participated in the 2NN study and the CHARM study in order to see if the beneficial effect of using nevirapine continues up to 144 weeks of treatment.

Conditions

  • HIV Infections

Interventions

DRUG

stavudine

DRUG

lamivudine

DRUG

nevirapine

DRUG

efavirenz

DRUG

trizivir

Sponsors & Collaborators

  • Boehringer Ingelheim

    collaborator INDUSTRY

  • International Antiviral Therapy Evaluation Center

    lead OTHER

Principal Investigators

  • Joep MA Lange, MD PhD · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

  • Mark Bloch, MD · Holdsworth House General Practice

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Completion
2007-04-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00127972 on ClinicalTrials.gov